Metabolic and endocrinal effects of N-desmethyl-olanzapine in mice with obesity: Implication for olanzapine-associated metabolic changes
Sign Up to like & getrecommendations! Published in 2019 at "Psychoneuroendocrinology"
DOI: 10.1016/j.psyneuen.2019.06.017
Abstract: Clinical use of the antipsychotic drug olanzapine (OLA) is associated with metabolic side effects to variable degrees. N-desmethyl-olanzapine (DMO) is one major metabolite of OLA, but its potential involvement in the metabolic responses remains unclear.… read more here.
Keywords: metabolic endocrinal; associated metabolic; mice; desmethyl olanzapine ... See more keywords